Immunobiological barriers to xenotransplantation

Area of Science:

• Transplantation immunology
• Xenotransplantation
• Genetic engineering

Background:

• Human anti-pig antibodies, particularly anti-galactose-α1,3-galactose (Gal), trigger hyperacute rejection of pig organs.
• Humoral and cellular immune responses, along with coagulation discrepancies, lead to graft destruction and thrombotic microangiopathy in xenotransplantation.
• Current immunosuppressive strategies alone are insufficient to prevent xenograft rejection.

Purpose of the Study:

• To investigate the efficacy of genetically engineered pigs in overcoming xenograft rejection barriers.
• To evaluate the impact of modifying pig antigens and expressing human regulatory proteins on xenograft survival.
• To assess the combined effect of genetic modification and immunosuppression in xenotransplantation.

Main Methods:

• Genetically modifying pigs to eliminate Gal antigen expression.
• Introducing human complement and coagulation regulatory proteins into pigs.
• Assessing xenograft survival in nonhuman primates receiving organs from genetically modified pigs.
• Administering effective immunosuppressive regimens to recipients.

Main Results:

• Genetically engineered pig organs lacking Gal antigen and expressing human regulatory proteins demonstrated prolonged survival in nonhuman primates.
• Eliminating Gal antigen and providing human regulatory proteins mitigated hyperacute rejection and thrombotic complications.
• The combination of genetic modification and immunosuppression was associated with successful xenograft outcomes.

Conclusions:

• Genetic engineering of donor pigs is a highly effective strategy to overcome major immunological barriers in xenotransplantation.
• Modifying pigs to express human regulatory proteins and lack specific antigens is critical for successful xenograft acceptance.
• This approach holds significant promise for advancing the field of xenotransplantation and addressing organ shortages.